For the Inventor, By the Inventor

Enter assignee name

Toronto, Canada

Deep Genomics Incorporated

Calculating rank

USPTO Granted Patents = 13

EPO Patents = 2

Trademarks = 2

Forward Citations = 54

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Brendan John Frey (11 out of 12 patents)

Hui Yuan Xiong (7 out of 7 patents)

Andrew Delong (6 out of 6 patents)

4. Babak Alipanahi (2 out of 2 patents)

5. Leo J Lee (2 out of 2 patents)

6. Hannes Bretschneider (2 out of 2 patents)

7. Daniele Merico (2 out of 2 patents)

8. Erno Wienholds (2 out of 2 patents)

9. Andrew Thomas DeLong (2 out of 2 patents)

10. Michael K K Leung (2 out of 2 patents)

11. Michael Ka Kit Leung (1 out of 14 patents)

12. Joao Antonio Lourenco Goncalves (1 out of 1 patent)

13. Mark George Ford Sun (1 out of 1 patent)

14. Frank Schmitges (1 out of 1 patent)

15. Matthew O'Hara (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 12626782 - Architectures for training neural networks using biological sequences, conservation, and molecular phenotypes (2026-05-12),

2. 11887696 - Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network (2024-01-30),

3. 11769073 - Methods and systems for producing an expanded training set for machine learning using biological sequences (2023-09-26),

4. 11681917 - System and method for training neural networks (2023-06-20),

5. 11636920 - Systems and methods for generating and training convolutional neural networks using biological sequences and relevance scores derived from structural, biochemical, population and evolutionary data (2023-04-25),

6. 11578327 - Oligonucleotide therapy for Wilson disease (2023-02-14),

7. 11568960 - Neural network architectures for scoring and visualizing biological sequence variations using molecular phenotype, and systems and methods therefor (2023-01-31),

8. 11427821 - Therapeutic splice-switching oligonucleotides (2022-08-30),

9. 11322225 - Systems and methods for determining effects of therapies and genetic variation on polyadenylation site selection (2022-05-03),

10. 11183271 - Neural network architectures for linking biological sequence variants based on molecular phenotype, and systems and methods therefor (2021-11-23),

11. 10885435 - System and method for training neural networks (2021-01-05),

12. 10410118 - System and method for training neural networks (2019-09-10),

13. 10185803 - Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network (2019-01-22),

Company Overview

Deep Genomics Incorporated, based in Toronto, specializes in the intersection of artificial intelligence and genomics. The company focuses on developing advanced computational tools to predict the effects of genetic variations on human health. By leveraging machine learning and deep learning techniques, Deep Genomics aims to accelerate drug discovery and optimize therapeutic strategies. Their innovative approach positions them at the forefront of precision medicine, addressing complex genetic disorders and enhancing patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#118 in Toronto

#1,167 in Canada

#45,104 in the World

Toronto, Canada

Deep Genomics Incorporated

Forward Citations = 54

14 inventors:

Brendan John Frey (11 out of 12 patents)

Hui Yuan Xiong (7 out of 7 patents)

Andrew Delong (6 out of 6 patents)

4. Babak Alipanahi (2 out of 2 patents)

5. Leo J Lee (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Deep Genomics Incorporated. Retrieved from https://idiyas.com/company/deep-genomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…